89bio, Inc.

Equities

ETNB

US2825591033

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
8.26 ^USD	+0.12%		-9.03%	-26.05%

Apr. 17	89bio, Inc. Appoints Martin Babler to Its Board of Directors	CI
Apr. 03	89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing	MT

89bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023

February 29, 2024 at 04:11 pm EST

89bio, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 40.24 million compared to USD 24.6 million a year ago. Basic loss per share from continuing operations was USD 0.5 compared to USD 0.48 a year ago.
For the full year, net loss was USD 142.19 million compared to USD 102.03 million a year ago. Basic loss per share from continuing operations was USD 2 compared to USD 2.93 a year ago.

Latest news about 89bio, Inc.

89bio, Inc. Appoints Martin Babler to Its Board of Directors	Apr. 17	CI
89bio Insider Sold Shares Worth $575,153, According to a Recent SEC Filing	Apr. 03	MT
Sector Update: Health Care Stocks Gain Wednesday Afternoon	Mar. 27	MT
89bio's Liver Disease Drug Candidate Pegozafermin Gets EMA Priority Medicines Status	Mar. 27	MT
89bio, Inc. Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis with Fibrosis and Compensated Cirrhosis	Mar. 27	CI
89Bio, Inc. Announces Initiation of Its Phase 3 Enlighten Program Evaluating the Efficacy and Safety of Pegozafermin in Patients with Metabolic Dysfunction-Associated Steatohepatitis, Formerly Known as Nonalcoholic Steatohepatitis	Mar. 12	CI
North American Morning Briefing : Stock Futures -2-	Mar. 08	DJ
Evercore ISI Adjusts 89bio Price Target to $37 From $29, Maintains Outperform Rating	Mar. 07	MT
Top Premarket Gainers	Mar. 04	MT
HC Wainwright Cuts Price Target on 89bio to $31 From $32, Keeps Buy Rating	Mar. 01	MT
RBC Trims Price Target on 89bio to $14 From $15, Keeps Sector Perform, Speculative Risk	Mar. 01	MT
89bio, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Feb. 29	CI
North American Morning Briefing : Stock Futures -2-	Jan. 16	DJ
RBC Downgrades 89bio to Sector Perform From Outperform, Cuts Price Target to $15 From $24 on View for 'Quieter Year,' Keeps Speculative Risk	Jan. 12	MT
89bio Insider Sold Shares Worth $560,000, According to a Recent SEC Filing	Jan. 03	MT
HC Wainwright Cuts 89bio Price Target to $32 From $35, Maintains Buy Rating	Dec. 20	MT
89bio Prices Upsized $150 Million Offering of Common Shares, Pre-Funded Warrants	Dec. 07	MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	Dec. 07	MT
89bio Launches $125 Million Offering of Common Shares, Pre-Funded Warrants	Dec. 07	MT
Sector Update: Health Care Stocks Rise Late Afternoon	Dec. 04	MT
Sector Update: Health Care Stocks Rise Monday Afternoon	Dec. 04	MT
89bio Share Rise on Advance Into Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis	Dec. 04	MT
89bio, Inc. Reaches Alignment with the FDA and EMA on Phase 3 Program for Pegozafermin in Nonalcoholic Steatohepatitis	Dec. 04	CI
89bio Sees 'Positive' Long-Term Results From Phase 2b Study of Pegozafermin to Treat Nonalcoholic Steatohepatitis	Nov. 27	MT
89bio, Inc. Announces New Positive Long-Term Data from the ENLIVEN Phase 2B Trial of Pegozafermin in Patients with Nonalcoholic Steatohepatitis	Nov. 27	CI

Chart 89bio, Inc.

Duration

Period

More charts

Company Profile

89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Companyâs lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG). Pegozafermin is engineered to protect against proteolysis and reduce renal clearance and optimize its potency, enabling the potential use of a lower dosage/dose. Pegozafermin has been optimally constructed with two mutations via substitutions with natural amino acids at site-specific positions (173 and 176) toward the C-terminus end of the hormone. It conducted a Phase I clinical trial to evaluate the safety, tolerability and pharmacokinetics (PK) of pegozafermin.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.26 USD

Average target price

31.89 USD

Spread / Average Target

+286.06%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
89BIO, INC.	-26.05%	787M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.73B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs